Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +40.41%
#2 Bitway Bitway +29.57%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.57%
#4 Starpower Starpower +22.57%
#5 aelf aelf +18.30%
#6 Pons Pons +15.67%
#7 Decred Decred +12.50%
#8 Ribbita by Virtuals Ribbita by Virtuals +11.55%
#9 DAPPOS DAPPOS +9.30%
#10 Venom Venom +8.73%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Argenica Therapeutics Ltd Argenica Therapeutics Ltd

Argenica Therapeutics Ltd

AGN
Rangering i aksjer #30341
Argenica Therapeutics Limited, a biotechnology company, engages in the research... Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Aksjekurs
$0.13400411
Markedsverdi
$17.21M
Endring (1 dag)
-7.32%
Endring (1 år)
-70.34%
Land
AU
Handel Argenica Therapeutics Ltd (AGN)

Kategori

Healthcare
P/B-forhold for Argenica Therapeutics Ltd (AGN)
P/B-forhold per 2026 TTM: 0
Ifølge Argenica Therapeutics Ltd sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Argenica Therapeutics Ltd fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE